PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer

Zhuang, Feifei; Huang, Shaoyan; Liu, Lei

doi:10.1016/j.biocel.2024.106581

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhuang et al found that pyrroline-5-carboxylate reductase (PYCR3) regulated mitochondrial gene expression by influencing mtDNA-CN, and its increased expression in triple-negative breast cancer (TNBC) predicted poor prognosis. Selective reduction in mtDNA-CN using the mtDNA replication inhibitor 2′,3′-dideoxycytidine in TNBC cell models resulted in decreased cell proliferation and reverted doxorubicin resistance through apoptosis induction [ 68 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Mitochondrial Copy Number in Neurodegenerative Diseases: Present Insights and Future Directions

Cerantonio,

Citrigno,

Greco

et al. 2024

IJMS

View full text Add to dashboard Cite

Neurodegenerative diseases are progressive disorders that affect the central nervous system (CNS) and represent the major cause of premature death in the elderly. One of the possible determinants of neurodegeneration is the change in mitochondrial function and content. Altered levels of mitochondrial DNA copy number (mtDNA-CN) in biological fluids have been reported during both the early stages and progression of the diseases. In patients affected by neurodegenerative diseases, changes in mtDNA-CN levels appear to correlate with mitochondrial dysfunction, cognitive decline, disease progression, and ultimately therapeutic interventions. In this review, we report the main results published up to April 2024, regarding the evaluation of mtDNA-CN levels in blood samples from patients affected by Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s diseases (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). The aim is to show a probable link between mtDNA-CN changes and neurodegenerative disorders. Understanding the causes underlying this association could provide useful information on the molecular mechanisms involved in neurodegeneration and offer the development of new diagnostic approaches and therapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Mitochondrial Copy Number in Neurodegenerative Diseases: Present Insights and Future Directions

Cerantonio,

Citrigno,

Greco

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer

Messeha,

Zarmouh,

Maku

et al. 2024

Cancers

View full text Add to dashboard Cite

Cell division cycle 20 homolog (CDC20) is a well-known regulator of cell cycle progression. Abnormal expression of CDC20 leads to mitotic defects, which play a significant role in cancer development. In breast cancer (BC), CDC20 has been identified as a biomarker that has been linked to poor patient outcomes. In this study, we investigated the association of CDC20 with BC prognosis and immune cell infiltration by using multiple online databases, including UALCAN, KM plotter, TIMER2.0, HPA, TNM-plot, bc-GenExMiner, LinkedOmics, STRING, and GEPIA. The results demonstrate that BC patients have an elevated CDC20 expression in tumor tissues compared with the adjacent normal tissue. In addition, BC patients with overexpressed CDC20 had a median survival of 63.6 months compared to 169.2 months in patients with low CDC20 expression. Prognostic analysis of the examined data indicated that elevated expression of CDC20 was associated with poor prognosis and a reduction of overall survival in BC patients. These findings were even more prevalent in chemoresistance triple-negative breast cancer (TNBC) patients. Furthermore, the Gene Set Enrichment Analysis tool indicated that CDC20 regulates BC cells’ cell cycle and apoptosis. CDC20 also significantly correlates with increased infiltrating B cells, CD4+ T cells, neutrophils, and dendritic cells in BC. In conclusion, the findings of this study suggest that CDC20 may be involved in immunomodulating the tumor microenvironment and provide evidence that CDC20 inhibition may serve as a potential therapeutic approach for the treatment of BC patients. In addition, the data indicates that CDC20 can be a reliable prognostic biomarker for BC.

show abstract

PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer

Cited by 2 publications

References 53 publications

The Role of Mitochondrial Copy Number in Neurodegenerative Diseases: Present Insights and Future Directions

The Role of Mitochondrial Copy Number in Neurodegenerative Diseases: Present Insights and Future Directions

Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer

Contact Info

Product

Resources

About